Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Azo-PROTAC-4C |
Target |
Action inhibitors |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC50H49ClN12O6S |
InChIKeyDYBUXZNKVNIICM-BCLHHTJESA-N |
CAS Registry2377513-21-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myeloid Leukemia | Preclinical | China | 10 Mar 2020 |